Treatment options for primary sclerosing cholangitis

References

• Chapman RW, Arborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut21(10), 870–877 (1980).
   PubMed Web of Science ®Google Scholar
• Lee YM, Kaplan MM. Primary sclerosing cholangitis. N. Engl. J. Med.332(14), 924–933 (1995).
   PubMed Web of Science ®Google Scholar
• Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology125(5), 1364–1369 (2003).
   PubMed Web of Science ®Google Scholar
• Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J. Gastroenterol. Hepatol.17(8), 908–913 (2002).
   PubMed Web of Science ®Google Scholar
• Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J. Hepatol.21(5), 787–791 (1994).
   PubMed Web of Science ®Google Scholar
• Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology126(7), 1929–1930 (2004).
   PubMed Web of Science ®Google Scholar
• Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol.33(1), 99–103 (1998).
   PubMed Web of Science ®Google Scholar
• Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis.26(1), 31–41 (2006).
   PubMed Web of Science ®Google Scholar
• LaRusso NF, Shneider BL, Black D et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology44(3), 746–764 (2006).
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand. J. Gastroenterol.17(2), 187–191 (1982).
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Franke A, Melum E et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology138(3), 1102–1111 (2010).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol.51(2), 237–267 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis (PSC). Hepatology51(2), 660–678 (2010).
   PubMed Web of Science ®Google Scholar
• Lewin M, Vilgrain V, Ozenne V et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology50(2), 528–537 (2009).
   PubMed Web of Science ®Google Scholar
• Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am. J. Gastroenterol.98(5), 1155–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology44(5), 1063–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am. J. Gastroenterol.95(5), 1130–1138 (2000).
   PubMed Web of Science ®Google Scholar
• Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology35(6), 1494–1500 (2002).
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Olsson R, Bergquist A et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology134(4), 975–980 (2008).
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology45(6), 1547–1554 (2007).
   PubMed Web of Science ®Google Scholar
• Zen Y, Fujii T, Harada K et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology45(6), 1538–1546 (2007).
   PubMed Web of Science ®Google Scholar
• Ghazale A, Chari ST, Zhang L et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology134(3), 706–715 (2008).
   PubMed Web of Science ®Google Scholar
• Gohlke F, Lohse AW, Dienes HP et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol.24(6), 699–705 (1996).
   PubMed Web of Science ®Google Scholar
• Floreani A, Rizzotto ER, Ferrara F et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am. J. Gastroenterol.100(7), 1516–1522 (2005).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology33(3), 544–553 (2001).
   PubMed Web of Science ®Google Scholar
• Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology36(6), 1393–1399 (2002).
   PubMed Web of Science ®Google Scholar
• Broome U, Olsson R, Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut38(4), 610–615 (1996).
   PubMed Web of Science ®Google Scholar
• Farrant JM, Hayllar KM, Wilkinson ML et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology100(6), 1710–1717 (1991).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology10(4), 430–436 (1989).
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology38(1), 210–217 (2003).
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Chait P, Wade JA et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology22(5), 1415–1422 (1995).
   PubMed Web of Science ®Google Scholar
• Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology92(6), 1869–1875 (1987).
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, Vrouenraets SM, Prawirodirdjo W et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut51(4), 562–566 (2002).
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am. J. Gastroenterol.102(1), 107–114 (2007).
   PubMed Web of Science ®Google Scholar
• Porayko MK, Wiesner RH, LaRusso NF et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology98(6), 1594–1602 (1990).
   PubMed Web of Science ®Google Scholar
• Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol.36(3), 321–327 (2002).
   PubMed Web of Science ®Google Scholar
• Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc.75(7), 688–694 (2000).
   PubMed Web of Science ®Google Scholar
• Boberg KM, Rocca G, Egeland T et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology35(3), 652–657 (2002).
   PubMed Web of Science ®Google Scholar
• Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int.28(7), 983–989 (2008).
   PubMed Web of Science ®Google Scholar
• Aadland E, Schrumpf E, Fausa O et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol.22(6), 655–664 (1987).
   PubMed Web of Science ®Google Scholar
• Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology100(5 Pt 1), 1319–1323 (1991).
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand. J. Gastroenterol.32(6), 604–610 (1997).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Harewood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut54(1), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand. J. Gastroenterol.15(6), 689–697 (1980).
   PubMed Web of Science ®Google Scholar
• Verdonk RC, Dijkstra G, Haagsma EB et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am. J. Transplant.6(6), 1422–1429 (2006).
   PubMed Web of Science ®Google Scholar
• O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin. Liver Dis.26(1), 3–21 (2006).
   PubMed Web of Science ®Google Scholar
• Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet359(9301), 150–157 (2002).
   PubMed Web of Science ®Google Scholar
• Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J. Gastroenterol.14(21), 3350–3359 (2008).
   PubMed Web of Science ®Google Scholar
• Broome U, Lofberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis. Colon Rectum38(12), 1301–1305 (1995).
   PubMed Web of Science ®Google Scholar
• Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case–control study. Dis. Colon Rectum40(4), 451–456 (1997).
   PubMed Web of Science ®Google Scholar
• Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut38(2), 234–239 (1996).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, LaRusso NF, Dozois RR, Beaver SJ. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology90(2), 316–322 (1986).
   PubMed Web of Science ®Google Scholar
• Brentnall TA, Haggitt RC, Rabinovitch PS et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology110(2), 331–338 (1996).
   PubMed Web of Science ®Google Scholar
• Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut41(4), 522–525 (1997).
   PubMed Web of Science ®Google Scholar
• Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am. J. Gastroenterol.94(6), 1643–1649 (1999).
   PubMed Web of Science ®Google Scholar
• Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc.56(1), 48–54 (2002).
   PubMed Web of Science ®Google Scholar
• Angulo P, Therneau TM, Jorgensen A et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J. Hepatol.29(5), 729–735 (1998).
   PubMed Web of Science ®Google Scholar
• Campbell MS, Lichtenstein GR, Rhim AD, Pazianas M, Faust T. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int.25(2), 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl.12(9), 1390–1402 (2006).
   PubMed Web of Science ®Google Scholar
• Guichelaar MM, Schmoll J, Malinchoc M, Hay JE. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology46(4), 1198–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Brandt DJ, MacCarty RL, Charboneau JW, LaRusso NF, Wiesner RH, Ludwig J. Gallbladder disease in patients with primary sclerosing cholangitis. AJR Am. J. Roentgenol.150(3), 571–574 (1988).
   PubMed Web of Science ®Google Scholar
• Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J. Hepatol.48(4), 598–605 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia–dysplasia–carcinoma sequence. Am. J. Surg. Pathol.31(6), 907–913 (2007).
   PubMed Web of Science ®Google Scholar
• Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol.97(5), 1138–1142 (2002).
   PubMed Web of Science ®Google Scholar
• Treeprasertsuk S, Sinakos E, Keach J, Lindor K. Long-term outcome of gallbladder polyps in patients with primary sclerosing cholangitis. Gastroenterology138(5), S787 (2010).
   Google Scholar
• Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol.99(3), 523–526 (2004).
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology48(4), 1106–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol.50(1), 158–164 (2009).
   PubMed Web of Science ®Google Scholar
• Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig. Dis. Sci.52(11), 3123–3135 (2007).
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Pitt HA, Nakeeb A et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J. Gastrointest. Surg.3(4), 357–367; discussion 367–368 (1999).
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am. J. Gastroenterol.102(8), 1677–1682 (2007).
   PubMed Web of Science ®Google Scholar
• Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl.6(6 Suppl. 2), S30–S34 (2000).
   Web of Science ®Google Scholar
• Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg.242(3), 451–458; discussion 458–461 (2005).
   PubMed Web of Science ®Google Scholar
• Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19–19 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci.50(9), 1734–1740 (2005).
   PubMed Web of Science ®Google Scholar
• Albert MB Steinberg WM, Henry JP. Elevated serum levels of tumor markers CA 19–19 in acute cholangitis. Dig. Dis. Sci.33, 1223–1225 (1988).
   PubMed Web of Science ®Google Scholar
• Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19–9 and CEA. Ann. Clin. Biochem.35(Pt 1), 99–103 (1998).
   PubMed Web of Science ®Google Scholar
• Murray MD, Burton FR, Di Bisceglie AM. Markedly elevated serum CA 19–19 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J. Clin. Gastroenterol.41(1), 115–117 (2007).
   PubMed Web of Science ®Google Scholar
• Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J. Hepatol.45(4), 568–574 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno Luna LE, Kipp B, Halling KC et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology131(4), 1064–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Siqueira E, Schoen RE, Silverman W et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest. Endosc.56(1), 40–47 (2002).
   PubMed Web of Science ®Google Scholar
• Bangarulingam SY, Bjornsson E, Enders F et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology51(1), 174–180 (2010).
   PubMed Web of Science ®Google Scholar
• Awadallah NS, Chen YK, Piraka C, Antillon MR, Shah RJ. Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am. J. Gastroenterol.101(2), 284–291 (2006).
   PubMed Web of Science ®Google Scholar
• Shah RJ, Langer DA, Antillon MR, Chen YK. Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. Clin. Gastroenterol. Hepatol.4(2), 219–225 (2006).
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Kruger M, Trautwein C et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy38(7), 665–669 (2006).
   PubMed Web of Science ®Google Scholar
• LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology95(4), 1036–1042 (1988).
   PubMed Web of Science ®Google Scholar
• Olsson R, Broome U, Danielsson A et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology108(4), 1199–1203 (1995).
   PubMed Web of Science ®Google Scholar
• Angulo P, MacCarty RL, Sylvestre PB et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci.47(1), 157–161 (2002).
   PubMed Web of Science ®Google Scholar
• van Milligen de Wit AW, Kuiper H, Camoglio L et al. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J. Gastroenterol. Hepatol.11(2), 129–136 (1999).
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol.95(9), 2338–2342 (2000).
   PubMed Web of Science ®Google Scholar
• Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci.49(1), 1–4 (2004).
   PubMed Web of Science ®Google Scholar
• Hommes DW, Erkelens W, Ponsioen C et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J. Clin. Gastroenterol.42(5), 522–526 (2008).
   PubMed Web of Science ®Google Scholar
• Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol.95(9), 2333–2337 (2000).
   PubMed Web of Science ®Google Scholar
• Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology106(2), 494–499 (1994).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut34(2), 242–246 (1993).
   PubMed Web of Science ®Google Scholar
• Sterling RK, Salvatori JJ, Luketic VA et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment. Pharmacol. Ther.20(9), 943–949 (2004).
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol.100(2), 308–312 (2005).
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int.27(4), 451–453 (2007).
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Carroll P, Abu-Elmagd K et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol.90(3), 455–459 (1995).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am. J. Gastroenterol.91(3), 511–515 (1996).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am. J. Gastroenterol.86(1), 57–61 (1991).
   PubMed Web of Science ®Google Scholar
• Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann. Intern. Med.131(12), 943–946 (1999).
   PubMed Web of Science ®Google Scholar
• van Hoogstraten HJ, Vleggaar FP, Boland GJ et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian–Dutch PSC Study Group. Am. J. Gastroenterol.95(8), 2015–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Elfaki DA, Lindor KD. Antibiotics for the treatment of primary sclerosing cholangitis. Am. J. Ther. DOI: 10.1097/MJT.0b013e3181b7b8c0 (2009) (Epub ahead of print).
   Google Scholar
• Farkkila M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology40(6), 1379–1386 (2004).
   PubMed Web of Science ®Google Scholar
• Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr.47(1), 61–67 (2008).
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am. J. Gastroenterol.104(1), 83–88 (2009).
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J. Hepatol.35(1), 134–146 (2001).
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology16(3), 707–714 (1992).
   PubMed Web of Science ®Google Scholar
• Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J. Hepatol.20(1), 57–64 (1994).
   PubMed Web of Science ®Google Scholar
• Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med.336(10), 691–695 (1997).
   PubMed Web of Science ®Google Scholar
• Cullen SN, Rust C, Fleming K et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J. Hepatol.48(5), 792–800 (2008).
   PubMed Web of Science ®Google Scholar
• Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. J. Gastroenterol.96(5), 1558–1562 (2001).
   PubMed Web of Science ®Google Scholar
• Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology121(4), 900–907 (2001).
   PubMed Web of Science ®Google Scholar
• Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology129(5), 1464–1472 (2005).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology50(3), 808–814 (2009).
   PubMed Web of Science ®Google Scholar
• Angulo P, Bharucha AE, Jorgensen RA et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig. Dis. Sci.44(3), 602–607 (1999).
   PubMed Web of Science ®Google Scholar
• Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J. Gastroenterol. Hepatol.13(2), 171–175 (2001).
   PubMed Web of Science ®Google Scholar
• Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J. Clin. Gastroenterol.31(4), 292–296 (2000).
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig. Dis. Sci.53(6), 1716–1720 (2008).
   PubMed Web of Science ®Google Scholar
• Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J. Gastroenterol. Hepatol.20(7), 688–692 (2008).
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J. Hepatol.36(2), 151–156 (2002).
   PubMed Web of Science ®Google Scholar
• Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J. Gastroenterol. Hepatol.8(7), 685–691 (1996).
   PubMed Web of Science ®Google Scholar
• Campbell WL, Peterson MS, Federle MP et al. Using CT and cholangiography to diagnose biliary tract carcinoma complicating primary sclerosing cholangitis. AJR Am. J. Roentgenol.177(5), 1095–1100 (2001).
   PubMed Web of Science ®Google Scholar
• Lindberg B, Arnelo U, Bergquist A et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy34(11), 909–916 (2002).
   PubMed Web of Science ®Google Scholar
• Rudolph G, Gotthardt D, Kloters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J. Hepatol.51(1), 149–155 (2009).
   PubMed Web of Science ®Google Scholar
• Hammel P, Couvelard A, O’Toole D et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med.344(6), 418–423 (2001).
   PubMed Web of Science ®Google Scholar
• Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Semin. Liver Dis.26(1), 62–68 (2006).
   PubMed Web of Science ®Google Scholar
• Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest. Endosc.53(3), 308–312 (2001).
   PubMed Web of Science ®Google Scholar
• Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J. Clin. Gastroenterol.42(9), 1032–1039 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson GK, Saeian K, Geenen JE. Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation. Curr. Gastroenterol. Rep.8(2), 147–155 (2006).
   PubMedGoogle Scholar
• Ahrendt SA, Pitt HA, Kalloo AN et al. Primary sclerosing cholangitis: resect, dilate, or transplant? Ann. Surg.227(3), 412–423 (1998).
   PubMed Web of Science ®Google Scholar
• Gaing AA, Geders JM, Cohen SA, Siegel JH. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am. J. Gastroenterol.88(12), 2000–2008 (1993).
   PubMed Web of Science ®Google Scholar
• Kaya M, Petersen BT, Angulo P et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am. J. Gastroenterol.96(4), 1059–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am. J. Gastroenterol.94(9), 2403–2407 (1999).
   PubMed Web of Science ®Google Scholar
• van den Hazel SJ, Wolfhagen EH, van Buuren HR, van de Meeberg PC, Van Leeuwen DJ. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy32(10), 779–782 (2000).
   PubMed Web of Science ®Google Scholar
• Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J. Gastroenterol. Hepatol.18(1), 69–74 (2006).
   PubMed Web of Science ®Google Scholar
• Cameron JL, Pitt HA, Zinner MJ et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. Ann. Surg.207(5), 614–622 (1988).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Olbrecht VA, Pitt HA et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. J. Am. Coll. Surg.206(5), 822–830; discussion 830–832 (2008).
   PubMed Web of Science ®Google Scholar
• Myburgh JA. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. Arch. Surg.129(10), 1057–1062 (1994).
   PubMedGoogle Scholar
• Brandsaeter B, Broome U, Isoniemi H et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl.9(9), 961–969 (2003).
   PubMed Web of Science ®Google Scholar
• Welsh FK, Wigmore SJ. Roux-en-Y choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation77(4), 602–604 (2004).
   PubMed Web of Science ®Google Scholar
• Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin. Liver Dis.26(1), 69–79 (2006).
   PubMed Web of Science ®Google Scholar
• Mathis KL, Dozois EJ, Larson DW et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br. J. Surg.95(7), 882–886 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation69(8), 1633–1637 (2000).
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Friman S, Broome U et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand. J. Gastroenterol.38(11), 1176–1183 (2003).
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Wiesner RH, Marotta PJ et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology30(5), 1121–1127 (1999).
   PubMed Web of Science ®Google Scholar
• Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl.10(7), 886–897 (2004).
   PubMed Web of Science ®Google Scholar
• Egawa H, Taira K, Teramukai S et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig. Dis. Sci.54(6), 1347–1354 (2009).
   PubMed Web of Science ®Google Scholar
• Kashyap R, Mantry P, Sharma R et al. Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis. J. Gastrointest. Surg.13(8), 1480–1486 (2009).
   PubMed Web of Science ®Google Scholar
• Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int.27(1), 86–94 (2007).
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin. Transpl.17–37 (1998).
   PubMedGoogle Scholar
• Dvorchik I, Subotin M, Demetris AJ et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology35(2), 380–384 (2002).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut43(5), 639–644 (1998).
   PubMed Web of Science ®Google Scholar
• Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther.18(1), 33–44 (2003).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Aguilar HI, Sandborn WJ et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology27(3), 685–690 (1998).
   PubMed Web of Science ®Google Scholar
• Vera A, Gunson BK, Ussatoff V et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation75(12), 1983–1988 (2003).
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Wiesner RH, Batts KP et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology29(4), 1050–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl.12(12), 1813–1824 (2006).
   PubMed Web of Science ®Google Scholar
• Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.14(2), 245–251 (2008).
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Schrumpf E, Bentdal O et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl.11(11), 1361–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Trotter JF et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl.14(2), 181–185 (2008).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.14(2), 138–143 (2008).
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Spiegelman P, Osgood MJ et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.9(7), 727–732 (2003).
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Lindor KD. Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers? Liver Transpl.14(2), 130–132 (2008).
   PubMed Web of Science ®Google Scholar
• Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl.15(3), 330–340 (2009).
   PubMed Web of Science ®Google Scholar
• Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int.21(5), 459–465 (2008).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology50(1), 291–308 (2009).
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann. Intern. Med.123(3), 161–167 (1995).
   PubMed Web of Science ®Google Scholar
• Tabibian N. Rifampin as antipruritic agent in primary sclerosing cholangitis. Am. J. Gastroenterol.84(3), 340 (1989).
   PubMed Web of Science ®Google Scholar
• Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol.102(7), 1528–1536 (2007).
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology113(4), 1264–1269 (1997).
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology45(3), 666–674 (2007).
   PubMed Web of Science ®Google Scholar
• Bellmann R, Graziadei IW, Feistritzer C et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl.10(1), 107–114 (2004).
   PubMed Web of Science ®Google Scholar
• Pares A, Cisneros L, Salmeron JM et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol.99(6), 1105–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am. J. Gastroenterol.104(4), 855–860 (2009).
   PubMed Web of Science ®Google Scholar
• Bjornsson ES, Kilander AF, Olsson RG. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis – a study of bile cultures from ERCP. Hepatogastroenterology47(36), 1504–1508 (2000).
   PubMed Web of Science ®Google Scholar
• Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment. Pharmacol. Ther.31(5), 537–547 (2010).
   PubMed Web of Science ®Google Scholar
• Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case–control study. Surgery138(4), 631–637; discussion 637–639 (2005).
   PubMed Web of Science ®Google Scholar
• Kartheuser AH, Dozois RR, LaRusso NF, Wiesner RH, Ilstrup DM, Schleck CD. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin. Proc.71(8), 748–756 (1996).
   PubMed Web of Science ®Google Scholar
• Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis. Colon Rectum46(2), 173–178 (2003).
   PubMed Web of Science ®Google Scholar
• Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm. Bowel Dis.11(3), 314–321 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez JD, Stratagoules ED, LaRue JM et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr. Cancer31(2), 111–118 (1998).
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med.134(2), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment. Pharmacol. Ther.22(9), 783–788 (2005).
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology124(4), 889–893 (2003).
   PubMed Web of Science ®Google Scholar
• Collier J. Bone disorders in chronic liver disease. Hepatology46(4), 1271–1278 (2007).
   PubMed Web of Science ®Google Scholar
• Zein CO, Jorgensen RA, Clarke B et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology42(4), 762–771 (2005).
   PubMed Web of Science ®Google Scholar
• Kaya M, de Groen PC, Angulo P et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am. J. Gastroenterol.96(4), 1164–1169 (2001).
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Isoniemi H, Broome U et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J. Hepatol.40(5), 815–822 (2004).
   PubMed Web of Science ®Google Scholar
• Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J. Gastroenterol. Hepatol.19(6), 487–491 (2007).
   PubMed Web of Science ®Google Scholar
• Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J. Am. Coll. Surg.187(4), 358–364 (1998).
   PubMed Web of Science ®Google Scholar
• Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann. Surg.213(1), 21–25 (1991).
   PubMed Web of Science ®Google Scholar
• Ghali P, Marotta PJ, Yoshida EM et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl.11(11), 1412–1416 (2005).
   PubMed Web of Science ®Google Scholar
• Sudan D, DeRoover A, Chinnakotla S et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am. J. Transplant.2(8), 774–779 (2002).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Lacerda MA, Jorgensen RA et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am. J. Gastroenterol.93(9), 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin–angiotensin system: recent discoveries and clinical implications. J. Gastroenterol. Hepatol.23(9), 1327–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu J, Wu J, Frizell E et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology117(5), 1198–1204 (1999).
   PubMed Web of Science ®Google Scholar
• Biecker E, De Gottardi A, Neef M et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther.313(3), 952–961 (2005).
   PubMed Web of Science ®Google Scholar
• Bridle KR, Popa C, Morgan ML et al. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl.15(10), 1315–1324 (2009).
   PubMed Web of Science ®Google Scholar
• Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol.45(6), 786–796 (2006).
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Fiorotto R, Fickert P et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology49(6), 1972–1981 (2009).
   PubMed Web of Science ®Google Scholar
• Hofmann AF, Zakko SF, Lira M et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology42(6), 1391–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin. Rev. Allergy Immunol.36(1), 52–61 (2009).
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem.45(17), 3569–3572 (2002).
   PubMedGoogle Scholar
• Fiorucci S, Antonelli E, Rizzo G et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology127(5), 1497–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Clerici C, Antonelli E et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther.313(2), 604–612 (2005).
   PubMed Web of Science ®Google Scholar
• Pall H, Zaman MM, Andersson C, Freedman SD. Decreased peroxisome proliferator activated receptor a is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator-/- mice. J. Pediatr. Gastroenterol. Nutr.42(3), 275–281 (2006).
   PubMed Web of Science ®Google Scholar
• Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology50(3), 671–673 (2009).
   PubMed Web of Science ®Google Scholar